Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy (Q35055978)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy |
scientific article |
Statements
1 reference
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy (English)
1 reference
Cheng Liao
1 reference
Jonathan Hsu
1 reference
Yong Kim
1 reference
Dong-Qing Hu
1 reference
Daigen Xu
1 reference
Jun Zhang
1 reference
Achal Pashine
1 reference
John Menke
1 reference
Toni Whittard
1 reference
Natasha Romero
1 reference
Theresa Truitt
1 reference
Michelle Slade
1 reference
Christine Lukacs
1 reference
Johannes Hermann
1 reference
Mingyan Zhou
1 reference
Matthew Lucas
1 reference
Satwant Narula
1 reference
Julie DeMartino
1 reference
Seng-Lai Tan
1 reference
4 October 2013
1 reference
1 reference
15
1 reference
5
1 reference
R146
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference